Alteration in Expression Profiles of a Series of Diabetes-Related Genes in db/db Mice Following Treatment With Thiazolidinediones

この論文にアクセスする

この論文をさがす

著者

    • Suzuki Akiko SUZUKI Akiko
    • Molecular Biological Research Laboratory and Exploratory Research Laboratories, Fujisawa Pharmaceutical Co., Ltd
    • Yasuno Toru YASUNO Toru
    • Molecular Biological Research Laboratory and Exploratory Research Laboratories, Fujisawa Pharmaceutical Co., Ltd
    • HIROSUMI Jiro
    • Molecular Biological Research Laboratory and Exploratory Research Laboratories, Fujisawa Pharmaceutical Co., Ltd
    • MUTOH Seitaro
    • Molecular Biological Research Laboratory and Exploratory Research Laboratories, Fujisawa Pharmaceutical Co., Ltd
    • NOTSU Yoshitada
    • Molecular Biological Research Laboratory and Exploratory Research Laboratories, Fujisawa Pharmaceutical Co., Ltd

抄録

We studied the effect of pioglitazone on the transcription of 42 genes associated with diabetes to examine the relationship between the antidiabetic action of thiazolidinediones(TZDs)and their ability to modulate transcription through their peroxisome proliferater−activated receptor(PPAR)−agonistic activity.Diabetic(db/db)mice were orally administered with pioglitazone for two weeks.Total RNA was prepared from liver, muscle and adipocytes and the quantity of mRNA was determined by comparative RT−PCR.The expression of diabetes−related genes was compared between lean and untreated db/db mice and between untreated and drug−treated db/db mice.The onset of diabetes was associated with a considerable alteration in the expression of a large number of diabetes−related genes.Treatment of db/db mice with pioglitazone modulated the expression of genes involved in the metabolism of glucose, lipids and lipoproteins.This included genes for phosphoenolpyruvate carboxykinase, β−oxidation enzymes, lipoprotein lipase, apolipoprotein AI and uncoupling proteins.Most of the genes responsible for insulin signaling were unaffected.Administration of pioglitazone was also shown to induce PPARγ expression in liver and muscle.It is therefore possible to hypothesize that TZDs may ameliorate diabetes through a mechanism of action involving a direct decrease in plasma glucose and triglyceride levels and improvements in free fatty acid−induced insulin resistance.

収録刊行物

  • The Japanese journal of pharmacology

    The Japanese journal of pharmacology 84(2), 113-123, 2000-10-01

    公益社団法人 日本薬理学会

参考文献:  58件中 1-58件 を表示

被引用文献:  1件中 1-1件 を表示

各種コード

  • NII論文ID(NAID)
    10008185422
  • NII書誌ID(NCID)
    AA00691188
  • 本文言語コード
    ENG
  • 資料種別
    ART
  • ISSN
    00215198
  • NDL 記事登録ID
    5549144
  • NDL 雑誌分類
    ZS51(科学技術--薬学)
  • NDL 請求記号
    Z53-D199
  • データ提供元
    CJP書誌  CJP引用  NDL  J-STAGE 
ページトップへ